Hepatocellular carcinoma

Where the papers sit

24 papers from the last 6 months study hepatocellular carcinoma directly · updated from PubMed 9 Oct 2026

• HCC Immune Biology

  Immune evasion and T-cell exhaustion are becoming central targets in liver cancer research. S100A10 is linked to CD8+ T-cell dysfunction, while coumarin, dark tea-derived vesicles, and related interventions seek to restore antitumor immune activity. Neoantigen transcripts, PCLAF, proteasome subunits, and circulating mRNA variants expand the search for immunotherapy targets and biomarkers. Spatial and multi-omics profiling are increasingly used to connect immune states with prognosis and treatment response.

  9 papers · 37.5%

• Oxidative Stress and Mitochondria

  Therapeutic strategies increasingly seek to kill liver cancer cells by overwhelming redox defenses and disrupting mitochondrial quality control. p-Coumaric acid, photodynamic therapy, and FeCo nanozyme patches promote ROS accumulation or oxidative injury, while mitophagy impairment adds mitochondrial stress. Autophagic flux, apoptosis, NRF2-related defenses, and TGM2 recur as determinants of treatment response. HIF1α-KLF4-driven hemoglobin expression links this biology to sorafenib resistance, leaving resistance reversal an open goal.

  5 papers · 20.8%

• AFP and PIVKA-II Biomarkers

  AFP and PIVKA-II are being combined with routine clinical variables to improve hepatocellular carcinoma detection and recurrence prediction. Early-detection models emphasize calibration, bootstrap validation, and clinically usable risk estimates rather than either marker alone. Perioperative laboratory indices extend these markers into postoperative surveillance. CRISPR/Cas12a electrochemical sensing points toward more engineered, sensitive biomarker assays.

  3 papers · 12.5%

• Others — HCC Risk and Treatment

  Risk, prognosis, screening, and treatment appear side by side without a single biological thread. Chronic hepatitis B adherence and machine-learning screening address population risk, while 5-hydroxytryptamine 3 receptor antagonists and atezolizumab plus bevacizumab relate to treatment outcomes. Other studies examine focal nodular hyperplasia, anti-synthetase syndrome, and arsenic nanozyme therapy. No consistent therapeutic or mechanistic direction emerges.

  7 papers · 29.2%